SCHEMBL1744877

SCHEMBL1744877

OC1CCc2cc(-c3ccccc3)ccc21

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GFRA3 O60609 1/20 0.62
RET P07949 1/20 0.62
CAMK2A Q9UQM7 1/20 0.50
PGR P06401 2/20 0.49
KDM1A O60341 2/20 0.44
KDM1B Q8NB78 1/20 0.44
PPARD Q03181 1/20 0.42
GRIN1 Q05586 1/20 0.41
GRIN2B Q13224 1/20 0.41
LIPG Q9Y5X9 1/20 0.40
CYP11B1 P15538 2/20 0.40
CYP11B2 P19099 2/20 0.40
CYP1A2 P05177 1/20 0.40
DGAT1 O75907 1/20 0.39
CYP3A4 P08684 2/20 0.39
CYP17A1 P05093 1/20 0.39
FAAH O00519 2/20 0.39
ALOX5 P09917 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18462211 0.90 CAMK2A (0.55) GFRA3RETCAMK2APGRKDM1A
SCHEMBL19116602 0.86 GFRA3 (0.51) GFRA3RETPGRCYP11B1CYP11B2
SCHEMBL1745326 0.84 PGR (0.51) GFRA3RETCAMK2APGRKDM1A
SCHEMBL1745279 0.84 GFRA3 (0.50) GFRA3RETCAMK2APGRKDM1A
SCHEMBL1745534 0.84 CYP17A1 (0.55) GFRA3RETCAMK2APGRKDM1A
SCHEMBL21126509 0.82 GRIN1 (0.58) GFRA3RETPPARDGRIN1GRIN2B
SCHEMBL28755063 0.81 GFRA3 (0.48) GFRA3RETCAMK2APGRKDM1A
SCHEMBL5444380 0.81 PGR (0.59) GFRA3RETPGRCYP11B1CYP11B2
SCHEMBL1744785 0.80 PGR (0.48) GFRA3RETPGRKDM1APPARD
SCHEMBL5439689 0.80 PGR (0.61) GFRA3RETPGRPPARDCYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
CN-1735408-A Receptor function controlling agent TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2006-02-15 CN disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR GFRA3 412/4885RET 528/4885CAMK2A 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.